Moteur de recherche d’entreprises européennes
Financement de l’UE (4 872 250 €) : Un ange gardien numérique qui améliore le bien-être des patients atteints de cancer et l’amélioration de leur état de santé après le traitement. Hor08/11/2019 Programme de recherche et d'innovation de l'UE « Horizon »
Vue d’ensemble
Texte
Un ange gardien numérique qui améliore le bien-être des patients atteints de cancer et l’amélioration de leur état de santé après le traitement.
The burden of cancer is rising globally and is estimated to have reached 18.1 million new cases and 9.6 million cancer deaths in 2018. Despite the rising cancer incidence, improvements in early detection and therapeutic treatment have improved cancer survival. As a consequence, the number of cancer survivors is increasing globally, creating the need to improve not only treatment but also wellness and follow‐up care. Cancer treatment often involves combined modalities such as surgery, chemotherapy, and radiotherapy. In the past decades, more effective and targeted therapeutic modalities and less destructive cancer treatments have been developed such as immunotherapy and drug‐targeted therapy. Even so, cancer and its treatment have important physical and psychosocial sequelae. ONCORELIEF is a 36-month action that will leverage the above 6 drivers in order to skillfully and methodologically overcome technical challenges, by introducing new approaches that will allow the utilization of big datasets in order to develop a user-centered AI System to facilitate the integration of QoL assessment instruments through the use of PROMs and PREMs in order to improve post-treatment health status, increase the wellbeing, and follow‐up care of cancer patients. This will be achieved through an intuitive smart digital assistant (Guardian Angel), able to provide personalized support in post-treatment activities and tasks, suggest actions regarding the patients' overall health-status, improved wellbeing and active health-care and ultimately maintain him/her engaged on a wellness journey that will safeguard his/her health over the foreseeable prolonged post-cancer treatment period. To achieve this, ONCORELIEF builds on the combined knowhow of its interdisciplinary industry-driven consortium that brings together state-of-the-art technological skills, design thinking methodology and occupational psychology/health sciences.
| Alma Mater Studiorum - Universita DI Bologna | 181 250 € |
| Care Across Ltd. | 418 750 € |
| 256 250 € | |
| Exus Software Ltd. | 701 250 € |
| 0,00 € | |
| 221 875 € | |
| FRAUNHOFER GESELLSCHAFT ZUR FORDERUNG DER ANGEWANDTEN FORSCHUNG e. V. | 461 250 € |
| 368 750 € | |
| Istituto Romagnolo Per LO Studio DEI Tumori Dino Amadori - Irst Srl | 247 500 € |
| MCS DATALABS | 615 750 € |
| Maggioli S.p.A. | 409 375 € |
| Suite5 Data Intelligence Solutions Ltd. | 406 875 € |
| Timelex | 205 000 € |
| UNIVERSITAETSMEDIZIN DER JOHANNES GUTENBERG-UNIVERSITAET MAINZ | 378 375 € |
https://cordis.europa.eu/project/id/875392
Cette annonce se réfère à une date antérieure et ne reflète pas nécessairement l’état actuel.
Les visualisations de "Alma Mater Studiorum - Universita DI Bologna - Financement de l’UE (4 872 250 €) : Un ange gardien numérique qui améliore le bien-être des patients atteints de cancer et l’amélioration de leur état de santé après le traitement."
sont mis à disposition par
North Data
et peuvent être réutilisées selon les termes de la licence
Creative Commons CC-BY.
